Pelthos Therapeutics Financials

Pelthos Therapeutics (PTHS) reported $16.2M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

No, Pelthos Therapeutics (PTHS) reported a net income of -$43.3M in fiscal year 2025, with a net profit margin of -267.3%.

Pelthos Therapeutics (PTHS) reported diluted earnings per share of $-23.04 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Pelthos Therapeutics (PTHS) had EBITDA of -$30.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Pelthos Therapeutics (PTHS) had a gross margin of 75.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Pelthos Therapeutics (PTHS) had an operating margin of -200.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Pelthos Therapeutics (PTHS) had a net profit margin of -267.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Pelthos Therapeutics (PTHS) has a return on equity of -111.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Pelthos Therapeutics (PTHS) generated -$22.7M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Pelthos Therapeutics (PTHS) generated -$22.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Pelthos Therapeutics (PTHS) had $130.4M in total assets as of fiscal year 2025, including both current and long-term assets.

Pelthos Therapeutics (PTHS) invested $99K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Pelthos Therapeutics (PTHS) invested $1.2M in research and development during fiscal year 2025.

Yes, Pelthos Therapeutics (PTHS) spent $75K on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Pelthos Therapeutics (PTHS) had 3M shares outstanding as of fiscal year 2025.

Pelthos Therapeutics (PTHS) had a current ratio of 2.05 as of fiscal year 2025, which is generally considered healthy.

Pelthos Therapeutics (PTHS) had a debt-to-equity ratio of 2.35 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Pelthos Therapeutics (PTHS) had a return on assets of -33.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Pelthos Therapeutics (PTHS) had $18.0M in cash against an annual operating cash burn of $22.6M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Pelthos Therapeutics (PTHS) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Pelthos Therapeutics (PTHS) has an earnings quality ratio of 0.52x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Pelthos Therapeutics (PTHS) has an interest coverage ratio of -10.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Pelthos Therapeutics (PTHS) scores 18 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.